Physician profile
Mina Sun
NPI 1043234271
$2,381.03
in general payments reported to CMS, 2019-2025
25 companies · $294 in 2025
The $294 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $163 · 2021: $320 · 2022: $252 · 2023: $648 · 2024: $511 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,378 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,378.37 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $427.83 | 2020-2024 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $353.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $333.13 | 2022-2025 | Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $195.74 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $168.44 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.04 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $99.19 | 2019-2021 | |
| Astellas Pharma US INC | $89.92 | 2024-2025 | Veozah |
| Pfizer INC. | $83.51 | 2019-2025 | |
| Csl Behring | $76.76 | 2021-2024 | Hizentra |
| Lilly USA, LLC | $70.59 | 2021-2025 | Kisunla, Amyvid |
| Otsuka America Pharmaceutical, INC. | $65.52 | 2021-2023 | Rexulti |
| Biogen, INC. | $46.03 | 2020-2021 | |
| Amgen INC. | $39.45 | 2023 | Otezla, Repatha |
| Ibsa Pharma INC. | $29.01 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $27.44 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.58 | 2025 | Xifaxan |
| Smith+Nephew, INC. | $21.47 | 2023 | Collagenase Santyl |
| Novartis Pharmaceuticals Corporation | $20.99 | 2023 | |
| Exact Sciences Corporation | $20.14 | 2023 | Cologuard Collection Kit |
| Lundbeck LLC | $16.71 | 2024 | Rexulti |
| Gilead Sciences, INC. | $16.70 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $15.64 | 2021 | |
| Eisai INC. | $14.06 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mina Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.